ロイヤルティ･ファーマ
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.04 | $674M | $686M |
| 2026 Q1 | 0.68 | $631M | $761M |
| 2025 Q4 | 0.64 | $622M | $827M |
| 2025 Q3 | 1.05 | $609M | $703M |
| 2025 Q2 | 0.09 | $579M | $364M |
| 2025 Q1 | 0.55 | $568M | $596M |
| 2024 Q4 |
| 0.47 |
| $594M |
| $743M |
| 2024 Q3 | 1.22 | $565M | $704M |